|
|
| | CELECOXIB-D7 Basic information |
| Product Name: | CELECOXIB-D7 | | Synonyms: | CELECOXIB-D7;4-[5-[2,3,5,6-tetradeuterio-4-(trideuteriomethyl)phenyl]-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide;[2H7]-Celecoxib;Celecoxib D7Q: What is
Celecoxib D7 Q: What is the CAS Number of
Celecoxib D7 Q: What is the storage condition of
Celecoxib D7 Q: What are the applications of
Celecoxib D7;Celecoxiβ-d7;4-[5-[4-(methyl-d3)phenyl-2,3,5,6-d4]-3-(trifluoromethyl)-1H-pyrazol-1-yl]-benzenesulfonamide;D7-Celecoxib;Celecoxib-D7 (Standard) | | CAS: | 544686-21-7 | | MF: | C17H7D7F3N3O2S | | MW: | 388.42 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File |  |
| | CELECOXIB-D7 Chemical Properties |
| Boiling point | 529.013±60.00 °C(Press: 760.00 Torr)(predicted) | | density | 1.431±0.14 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | storage temp. | Store at -20°C | | solubility | DMSO: 76 mg/ml,Ethanol: 33 mg/ml | | form | A solid | | pka | 9.676±0.10(predicted) | | color | Off-white to gray |
| | CELECOXIB-D7 Usage And Synthesis |
| Description | Celecoxib-d7 is intended for use as an internal standard for the quantification of celecoxib by GC- or LC-MS. Celecoxib is a selective inhibitor of COX-2 (IC50s = 22.9 and 0.05 μM for COX-1 and COX-2, respectively). It displays chemopreventive activity in multiple tumor types via proapoptotic effects that are independent of COX-2 inhibition. Formulations containing celecoxib have been used in the treatment of inflammation while circumventing the gastrointestinal toxicity associated with traditional non-sterodial anti-inflammatory drugs, however, the use of celecoxib has been tempered due to its ability to induce adverse cardiovascular events. | | Uses | Celecoxib-d7 is the labeled analogue of Celecoxib (C251000), a selective cyclooxygenase-2 (COX-2) inhibitor. Anti-inflammatory. Used in treatment of familial adenomatous polyposis. | | References | [1] MD.JASHIM UDDIN Edward E K P N Praveen Rao. Design and synthesis of novel celecoxib analogues as selective cyclooxygenase-2 (COX-2) inhibitors: replacement of the sulfonamide pharmacophore by a sulfonylazide bioisostere[J]. Bioorganic & Medicinal Chemistry, 2003, 11 23: Pages 5273-5280. DOI: 10.1016/j.bmc.2003.07.005
[2] I A MARDINI G A F. Selective inhibitors of cyclooxygenase-2: a growing class of anti-inflammatory drugs.[J]. Molecular interventions, 2001, 1 1: 30-38.
[3] VERENA JENDROSSEK Claus B René Handrick. Celecoxib activates a novel mitochondrial apoptosis signaling pathway[J]. FASEB Journal, 2003, 17 11: 1-25. DOI: 10.1096/fj.02-0947fje
[4] De Souza, F.I., Zumiotti, A.V., and Da Silva, C.F. Neuregulins 1-α and 1-β on the regeneration the peripheral nerves[J]. Acta Ortop Bras.
[5] JIUXIANG ZHU. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors.[J]. Cancer research, 2004, 64 12: 4309-4318. DOI: 10.1158/0008-5472.can-03-4063 |
| | CELECOXIB-D7 Preparation Products And Raw materials |
|